Evidence map›Paper›PMID 31319594›Full record

ArticleCancers2019

Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma.

Viola J Chen, Gabriela Hernandez-Meza, Prashasti Agrawal, Chiyuan A Zhang, Lijia Xie, Cynthia L Gong, Christian R Hoerner, Sandy Srinivas, Eric K Oermann, Alice C Fan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Bioinformatics Analysis of Prognostic Value ofInternational journal of general medicine · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. The role of immunotherapy in advanced renal cell carcinoma: Review.International braz j urol : official journal of the Brazilian Society of Urology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Viola J ChenDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Gabriela Hernandez-MezaIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Prashasti AgrawalDepartment of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Chiyuan A ZhangDepartment of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Lijia XieDepartment of Medicine, Highland Hospital, Oakland, CA 94602, USA.
Cynthia L GongDivision of Neonatology and the Fetal and Neonatal Institute, Children's Hospital Los Angeles (CHLA), Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Christian R HoernerDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Sandy SrinivasDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Eric K OermannDepartment of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Alice C FanDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. afan@stanford.edu.

Funding

Conquer Cancer Foundation CDANational Institutes of Health 5T32CA196585-02
6 · The paper itself

Abstract

With 15 drugs currently approved for the treatment of metastatic renal cell carcinoma (mRCC) and even more combination regimens with immunotherapy on the horizon, there remains a distinct lack of molecular biomarkers for therapeutic efficacy. Our study reports on real-world clinical outcomes of mRCC patients from a tertiary academic medical center treated with empirically selected standard-of-care therapy. We utilized the Stanford Renal Cell Carcinoma Database (RCCD) to report on various outcome measures, including overall survival (OS) and the median number of lines of targeted therapies received from the time of metastatic diagnosis. We found that most metastatic patients did not survive long enough to attempt even half of the available targeted therapies. We also noted that patients who failed to receive a clinical benefit within the first two lines of therapy could still go on to experience clinical benefit in later lines of therapy. The term, "clinical benefit" was assigned to a line of therapy if a patient remained on drug treatment for three months or longer. Moreover, patients with clinical benefit in at least one line of therapy experienced significantly longer OS compared to those who did not have clinical benefit in at least one line of therapy. Developing biomarkers that identify patients who will receive clinical benefit in individual lines of therapy is one potential strategy for achieving rational drug sequencing in mRCC.

Indexed as

favorable-, poor-, and intermediate-risk prognosis RCCIMDC criteriaimmunotherapykidney cancermetastatic renal cell carcinomaRCCsystemic treatmenttargeted kinase inhibitorstherapy sequencing

Identifiers

PMID31319594
PMCPMC6678132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.